PMID- 35088933
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220420
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 26
IP  - 5
DP  - 2022 Mar
TI  - Wharton's jelly-derived stromal cells and their cell therapy applications in 
      allogeneic haematopoietic stem cell transplantation.
PG  - 1339-1350
LID - 10.1111/jcmm.17105 [doi]
AB  - For decades, mesenchymal stromal cells (MSCs) have been of great interest in the 
      fields of regenerative medicine, tissue engineering and immunomodulation. Their 
      tremendous potential makes it desirable to cryopreserve and bank MSCs to increase 
      their accessibility and availability. Postnatally derived MSCs seem to be of 
      particular interest because they are harvested after delivery without ethical 
      controversy, they have the capacity to expand at a higher rate than adult-derived 
      MSCs, in which expansion decreases with ageing, and they have demonstrated 
      immunological and haematological supportive properties similar to those of 
      adult-derived MSCs. In this review, we focus on MSCs obtained from Wharton's 
      jelly (the mucous connective tissue of the umbilical cord between the amniotic 
      epithelium and the umbilical vessels). Wharton's jelly MSCs (WJ-MSCs) are a good 
      candidate for cellular therapy in haematology, with accumulating data supporting 
      their potential to sustain haematopoietic stem cell engraftment and to modulate 
      alloreactivity such as Graft Versus Host Disease (GVHD). We first present an 
      overview of their in-vitro properties and the results of preclinical murine 
      models confirming the suitability of WJ-MSCs for cellular therapy in haematology. 
      Next, we focus on clinical trials and discuss tolerance, efficacy and infusion 
      protocols reported in haematology for GVHD and engraftment.
CI  - (c) 2022 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Pochon, Cecile
AU  - Pochon C
AUID- ORCID: 0000-0003-0277-5611
AD  - Pediatric Oncohematology Department, CHRU Nancy, Universite de Lorraine, Nancy, 
      France.
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
FAU - Notarantonio, Anne-Beatrice
AU  - Notarantonio AB
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
FAU - Laroye, Caroline
AU  - Laroye C
AD  - Pediatric Oncohematology Department, CHRU Nancy, Universite de Lorraine, Nancy, 
      France.
AD  - Cell Therapy Unit, CHRU Nancy, Universite de Lorraine, Nancy, France.
FAU - Reppel, Loic
AU  - Reppel L
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
AD  - Cell Therapy Unit, CHRU Nancy, Universite de Lorraine, Nancy, France.
FAU - Bensoussan, Daniele
AU  - Bensoussan D
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
AD  - Cell Therapy Unit, CHRU Nancy, Universite de Lorraine, Nancy, France.
FAU - Bertrand, Allan
AU  - Bertrand A
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
FAU - Rubio, Marie-Therese
AU  - Rubio MT
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
FAU - D'Aveni, Maud
AU  - D'Aveni M
AD  - UMR 7365 CNRS, IMoPA, Universite de Lorraine, Nancy, France.
AD  - Hematology Department, CHRU Nancy, Universite de Lorraine, Nancy, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220128
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - *Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - Umbilical Cord
MH  - *Wharton Jelly
PMC - PMC8899189
OTO - NOTNLM
OT  - Wharton's jelly
OT  - applications
OT  - cell therapy
OT  - graft versus host disease
OT  - mesenchymal stem cells
OT  - stem cell transplantation
OT  - stromal cells
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/29 06:00
MHDA- 2022/04/21 06:00
PMCR- 2022/03/01
CRDT- 2022/01/28 08:39
PHST- 2021/10/30 00:00 [revised]
PHST- 2021/07/19 00:00 [received]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2022/01/28 08:39 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - JCMM17105 [pii]
AID - 10.1111/jcmm.17105 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2022 Mar;26(5):1339-1350. doi: 10.1111/jcmm.17105. Epub 2022 Jan 
      28.